Malignant glioma
Conditions
Interventions
Initial therapy: Temozolomide (75mg/m2/day), Day 1 to 45, po Vincristine (0.6mg/m2), Day2 and 3, iv IFN-beta (3MIU/body/day), 3 days/week, DIV, during radiotherapy Radiotherapy (60 Gy/30 fr), 5 d
Sponsors
Department of Neurosurgery, Hirosaki University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) For patients who undergo surgery for first relapse disease with histologically proven malignant glioma and could accept informed consent 2) Age is 16~80 yo 3) Tumor location is in supra-tentorial lesion without optic nerve, hypothalamus, brain stem and dissemination 4) Without experience of chemo-radiotherapy for other malignant tumor 5) Without past history of RT 6) Without double cancer 7) Eastern Cooperative Oncology Group(ECOG) performance scale(PS) 0-2 or PS3 with neurological deficit 8) With normal organic function 9) Without severe infection 10) This protocol would be able to start within 21 days 11) The rate of operation removal is not concern
Exclusion criteria
Exclusion criteria: Patients who did not satisfy inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2y-OS | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival: PFS 5y-OS Overall survival: OS PFS and OS with MGMT methylation status Adverse event | — |
Countries
Japan
Contacts
Public ContactKenichiro Asano
Hirosaki University School of Medicine Department of Neurosurgery
Outcome results
None listed